The
host defense peptide LL-37 is the only human cathelicidin,
characterized by pleiotropic activity ranging from immunological to
anti-neoplastic functions. However, its overexpression has been associated
with harmful inflammatory responses and apoptosis. Thus, for the latter
cases, the development of strategies aiming to reduce LL-37 toxicity
is highly desired as these have the potential to provide a viable
solution. Here, we demonstrate that the reduction of LL-37 toxicity
might be achieved by the impairment of its cell surface binding through
interaction with small organic compounds that are able to alter the
peptide conformation and minimize its cell penetration ability. In
this regard, the performed cell viability and internalization studies
showed a remarkable attenuation of LL-37 cytotoxicity toward colon
and monocytic cells in the presence of the polysulfonated drug suramin.
The mechanistic examinations of the molecular details indicated that
this effect was coupled with the ability of suramin to alter LL-37
secondary structure via the formation of peptide–drug
complexes. Moreover, a comparison with other therapeutic agents having
common features unveiled the peculiar ability of suramin to optimize
the binding to the peptide sequence. The newly discovered suramin
action is hoped to inspire the elaboration of novel repurposing strategies
aimed to reduce LL-37 cytotoxicity under pathological conditions.